UroAlerts - Prostate Cancer Weekly

June 30, 2026

Videos

Peer-to-Peer Clinical Conversations

CAPItello-281 Phase III Results and the Role of AKT Inhibition in mHSPC, Journal Club - Zachary Klaassen & Rashid Sayyid

Zachary Klaassen

Rashid Sayyid and Zachary Klaassen review CAPItello-281, a phase 3 trial of capivasertib plus abiraterone versus placebo plus abiraterone in 1,012 de novo PTEN-deficient metastatic hormone-sensitive prostate cancer patients, defined as 90% or greater PTEN loss on IHC.

A Real-World Study of mHSPC Patients: Comparative Survival with Apalutamide and Enzalutamide - Neal Shore

Neal Shore

Neeraj Agarwal speaks with Neal Shore about a real-world analysis comparing overall survival in patients with metastatic hormone-sensitive prostate cancer treated with apalutamide versus enzalutamide.

Beyond the Abstracts

Artificial Intelligence Defines Spatial Patterns of Tumor-Infiltrating Lymphocytes Highly Associated with Outcome - a Pan-GI Cancer Study - Beyond the Abstract

Optimizing [212Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts - Beyond the Abstract

Conference Coverage

SNMMI 2026: Impact of External Beam Radiotherapy Use and Timing on Clinical Outcomes in Patients Receiving 177Lu-PSMA-617 + Best Standard of Care: A Secondary Analysis from the VISION Trial

AUA 2026: Radiographic Progression-free Survival as a Meaningful Endpoint in Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TALAPRO-2 Randomized Clinical Trial

APCCC 2026: How to Make Best Use of Lutetium-PSMA Radioligand Therapy?

APCCC 2026: Debate: Patients with High-Risk Localized Prostate Cancer Need the Addition of an ARPI to Radiotherapy + Long-Term ADT – Against the Addition of ARPI to Radiotherapy + ADT

PSMA and Beyond 2026: Clinical Trial Updates: PEACE-6 PR Trial

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer.

Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.

Cancer-specific mortality of grade group 1 prostate cancer: Results from Surveillance, Epidemiology, and End Results Database, 2004-2021.

Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.

Deep learning classification of significant prostate cancer on MRI: a systematic review and meta-analysis.

Long-term trends in the burden of prostate cancer in the United States from 1990 to 2021: A detailed analysis based on the Global Burden of Disease Study 2021.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413.

Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI-PARP-Radioligand Era.

First Results Comparing MLC Versus IRIS CyberKnife Collimators in Prostate Stereotactic Body Radiation Therapy in an Italian Oncology Institute.

Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.

Contemporary Prostate Cancer Intraprostatic Imaging Scores: A Practical and Hands-on Guide for Urologists.

Post-diagnosis physical activity in relation to mortality among prostate cancer survivors: a systematic review and meta-analysis.

Incidence and Short- to Intermediate-Term Oncological Outcomes of Pathological T0 Prostate Cancer After Robot-Assisted Radical Prostatectomy: A Multicenter, Retrospective Cohort Study in Japan (MSUG94 Group).

Development and validation of a multimodal artificial intelligence-based model for predicting post-prostatectomy treatment outcomes from baseline biparametric prostate magnetic resonance imaging.

Integrative genomic profiling of newly diagnosed prostate cancers progressing on surveillance.

The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients with Prostate Cancer on Active Surveillance.

Optimal MRI sequence for predicting extraprostatic extension in prostate cancer: comparison of LCC and MaxRADD measurements.

Criteria Clinicians Use to Classify Patients as High Risk in Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer.

PANDA-PLUS: Improved Dataset of Prostate Whole Slide Images from PANDA Challenge with Pixel-Level Expert Annotations - Beyond the Abstract

Quantifying the Renal Impact of [177Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry - Beyond the Abstract

A Practical Guide to PSMA PET Radiopharmaceuticals for Prostate Cancer Imaging, From the AJR Special Series on Molecular Imaging.

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?

Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.

Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.

Clinically Significant Prostate Cancer in Patients Undergoing Holmium Laser Enucleation of Prostate for Benign Hyperplasia: A Preoperative Nomogram and a Postoperative Surveillance Protocol.

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC